Join Us | Latest Articles | Contact

Journal Home

Editorial Board


Submit to this journal

Current issue

International Journal of Neurology and Neurotherapy

DOI: 10.23937/2378-3001/2/2/1031

Corpora Amylacea in Neurodegenerative Diseases: Cause or Effect?

Troy T. Rohn*

Department of Biological Sciences, Boise State University, Boise, USA

*Corresponding author: Troy T. Rohn, Department of Biological Sciences, Boise State University, 1910 University Drive, Boise, ID 83725, USA, Tel: +1-208-426-2396, Fax: +1-208-426-1040, E-mail:
Int J Neurol Neurother, IJNN-2-031, (Volume 2, Issue 2), Review Article; ISSN: 2378-3001
Received: July 01, 2015 | Accepted: August 26, 2015 | Published: August 28, 2015
Citation: Rohn TT (2015) Corpora Amylacea in Neurodegenerative Diseases: Cause or Effect?. Int J Neurol Neurother 2:031. 10.23937/2378-3001/2/2/1031
Copyright: © 2015 Rohn TT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


The presence of corpora amylacea (CA) in the CNS is associated with both normal aging and neurodegenerative conditions including Alzheimer's disease (AD) and vascular dementia (VaD). CA are spherical bodies ranging in diameter (10-50 μm) and whose origin has been documented to be derived from both neural and glial sources. CA are reported to be primarily composed of glucose polymers, but approximately 4% of the total weight of CA is consistently composed of protein. CA are typically localized in the subpial, periventricular and perivascular regions within the CNS. The presence of CA in VaD has recently been documented and of interest was the localization of CA within the hippocampus proper. Despite numerous efforts, the precise role of CA in normal aging or disease is not known. The purpose of this mini review is to highlight the potential function of CA in various neurodegenerative disorders with an emphasis on the potential role if any these structures may play in the etiology of these diseases.


Corpora amylacea, Neurodegenerative disease, Vascular dementia, Pathology, Alzheimer's disease

Characteristics of Corpora Amylacea

Corpora amylacea (CA) were first described by Purkinje in 1837 in the brains of elderly patients. The presence of CA within the normal aging brain is well established and in addition, can also be seen in a variety of neurological conditions including Alzheimer's disease (AD), multiple sclerosis, hippocampal sclerosis and epilepsy [1-6]. Morphologically, CA represent as spherical translucent structures that range in diameter between 10-50μm with an average diameter of 15 μm [7,8]. Their internal structure is characterized by the presence of numerous short linear densities with a narrow rim of fibrils often seen at the periphery. Histochemical analysis indicates that CA are basophilic structures principally composed of polysaccharides and as such are easily identified using periodic acid-Schiff reagent or iodide (Figure 1A). In addition to polysaccharides, numerous proteins involved in aging and stress have been identified within CA including ubiquitin, heat-shock proteins [9], transglutaminases [10], anion exchange proteins [11], complement proteins [12], myelin basic protein [13], Bcl-2, c-Jun [14], NeuN [15], S100 proteins [16], thrombospondin-1, ADAMTS13 [17], reelin [18], tau [18-20], and alpha-synuclein [18] (Figure 1B).

Figure 1: Characteristic features of corpora amylacea in the CNS.
(A): CA are basophilic structures principally composed of polysaccharides and as such are easily identified using periodic acid-Schiff (PAS) reagent that labels CA as pink circular structures with varying diameters between 10-50μm. Depicted are numerous CA detected following labeling with PAS reagent in subpial regions in the hippocampus of a representative VaD case. Scale bar represents 10μm. (B): The major protein constituents that have been documented within CA are numerous and include both cytoskeletal proteins, stress proteins, and blood proteins. View Figure 1


Much debate has centered around the potential origin of CA within the CNS as either being derived from glial or neuronal cells. Historically, CA were interpreted as being glial in nature [7,21,22]. On the other hand, evidenced has suggested that CA are derived from neuronal sources [13,19,23-27]. It is noteworthy, that a recent study has provided compelling evidence that CA are derived from a glial source that involves heme oxygenase-1-mediated damage to mitochondria and CA biogenesis [28]. The authors came to these conclusions by using cultured astrocytes in which heme oxygenase-1 was over expressed to levels typically observed in the AD brain. CA-like cytoplasmic inclusions were consistently observed under these conditions within astrocytes that were not present in control cells [28].

With advancing age, CA are frequently found in the sub ependymal zones of the ventricles, localized in particular along the margin of blood vessels or beneath the pia [7]. The prevailing view suggests that because CA develop in the aged individuals with documented vascular disease and diabetes, that disturbances in the blood-brain barrier may underlie why CA develop mainly in the proximity of structures composing this barrier including the perivascular space, subpial and subependymal areas [29].

Presence of Corpora Amylacea in Neurodegenerative Diseases

CA accumulation in the CNS is associated with a number of neurodegenerative diseases. In AD, CA are present to a greater density as compared to normal aged subjects and can be identified by ubiquitin, tau, and heat-shock protein antibodies [9,19]. Renkawek and Bosman reported the presence of anion exchanger proteins within CA of the AD brain and their data supported an accumulation of neuronal proteins may be involved in the pathogenesis of CA in AD [11]. Although CA documented from both the brain of normal aging individuals versus AD showed morphological similarities, there have been reported differences, for example, in their size, biochemical and elemental composition [19].

CA have also been documented in hippocampal sclerosis and temporal lobe epilepsy [3-5,30-33]. In contrast to AD, CA in hippocampal sclerosis and temporal lobe epilepsy appear to localize predominantly within the hippocampal proper and not in perivascular regions. In addition, the distribution of CA parallels the neuronal cell loss associated with hippocampal sclerosis and the inverse correlation of CA density with neuronal cell densities suggests that CA may be the result of neuronal cell loss [4,5,34]. In a study by Cherian et al., the authors examined the role of CA in patients with mesial lobe epilepsy associated with temporal sclerosis. Their findings demonstrated that patients with the presence of CA in their hippocampi were significantly older and showed a trend towards having a longer duration of epilepsy as compared to patients who did not have CA [33].

In addition to AD, hippocampal sclerosis and temporal lobe epilepsy, CA have also been documented in other neurodegenerative diseases including multiple sclerosis [2,35], Parkinson's disease [10,36,37], Huntington's disease [38], and Pick's disease [12]. With regards to the finding of CA in multiple sclerosis, the authors concluded that the generation of CA are most likely a secondary phenomenon in the pathology of this disease [2]. Moreover, Selmaj et al. demonstrated that CA represent remnants of degenerated and aggregated neuronal cells [2].

Presence of Corpora Amylacea in Vascular Dementia

Vascular dementia (VaD) is a neurodegenerative disorder that accounts for roughly 15-20 percent of all types of dementia making it the second leading cause of dementia behind only AD in the USA [39]. Available data indicates that VaD shares several pathological features with AD, including the presence of neurofibrillary tangles (NFTs), amyloid or plaques, white matter lesions and cerebral amyloid angiopathy [40,41]. According to a recent analysis, pure vascular dementia (VaD) accounts for roughly 15-20 percent of all types of dementia making it the second leading cause of dementia behind only Alzheimer's disease in the USA [39]. One difficulty in measuring the prevalence of VaD is that it often coexists with Alzheimer-type lesions and other pathologies with 20-30 percent of demented subjects showing mixed pathologies [42]. Indeed, available data indicates that VaD and AD share several pathological features including the presence of neurofibrillary tangles (NFTs), amyloid or plaques, white matter lesions and cerebral amyloid angiopathy [40,41]. When VaD has concomitant AD pathology the symptoms are collectively referred to as being of "mixed dementia". Behaviorally, patients with VaD show loss in executive functions as an initial symptom, whereas in AD memory loss is often associated with the earliest known symptoms. Other important symptoms of VaD include confusion, language deficits, restlessness, agitation, and gait disturbances [43]. There are at least three pathological features commonly associated with VaD that include: 1) large artery infarctions, 2) small artery infarctions or lacunes that are generally subcortical, and 3) chronic subcortical ischemia leading to selective loss of neurons, glial cells, and endothelial cells [44].

We have recently demonstrated the presence of caspase-cleaved tau in the human VaD brain [45]. This study was accomplished utilizing a well-characterized antibody, TauC3 that detects caspase-cleaved tau truncated at Asp421 [46,47]. Using the TauC3 antibody, we showed the presence of caspase-cleaved tau within NFTs, neuropil threads, and CA. The presence of caspase-cleaved tau within CA was a consistent finding in all VaD cases examined [45]. Importantly, labeled CA were abundantly found only in the hippocampal proper, specifically within the dentate gyrus region. In addition, we were able to document the co-localization of TauC3 together with PHF-1, an antibody that detects paired-helical filaments (Figure 2). Co-localization of caspase-cleaved tau was also shown to occur with ubiquitin, one of the primary protein components of CA [9]. Taken together, these results support the notion that CA found in VaD contain truncated and aggregated tau. A recent report in post-mortem brain sections from mild cognitive impairment (MCI) subjects confirmed the localization of CA within the hippocampus and there were statistically greater numbers of CA relative to subjects classified as being cognitively normal [28].

Figure 2: Co-localization of caspase-cleaved tau with PHF-1 within corpora amylacea of the VaD brain.
Representative images from double-label immunofluorescence confocal analysis in VaD utilizing the TauC3 antibody that detects caspase-cleaved tau (green, far left panel) and PHF-1 (red, middle panel) with the overlap image shown indicating co-localization of the two markers (yellow, far right panel). The results revealed a fibrillar labeling by PHF-1 while that of TauC3 was more or less homogenous throughout CA. View Figure 2


Besides our study, Meng et al. also reported the presence of CA in VaD with the demonstration of the presence of two proteins, ADAMTS13 and thrombospondin-1, both highly expressed in blood [17]. The staining of thrombospondin-1 within CA had a halo appearance in some regions, but a more homogenous labeling in other regions [17]. Thrombospondin-1 labeling of CA was found in both normal and VaD cases, but the staining was more frequent and prominent in VaD cases [17]. In addition to thrombospondin-1, the authors also documented the immunoreactivity of the vascular protein, ADAMTS13 in VaD patients. The authors theorized that since the documented CA in VaD were found in perivascular regions, extravasated plasma proteins such as thrombospondin-1 and ADAMTS13, which could leak out of vessels over time, may contribute to the formation of CA [17]. Because VaD is a cerebral vascular disorder, the findings of plasma proteins ADAMTS13 and thrombospondin-1 within CA may not be surprising given the fact the blood-brain barrier is known to be compromised in VaD [48].

Potential Role of Corpora Amylacea in Vascular Dementia and Other Neurodegenerative Diseases

Although the presence of CA in normal aging and in various neurodegenerative diseases is now well documented, the precise role these structures play has remained elusive. Previous studies have suggested that CA could be important indicators of neurodegeneration. Singhrao et al. proposed that based on the composition of CA, namely the inclusion of ubiquinated proteins and the presence of complement factors that a function of CA could be to prevent the recognition of these immunogenic proteins by immune cells of the CNS and thus protect the CNS from inflammatory injury [12]. Others have supported this view that CA are involved in the sequestration of potentially deleterious cellular products including ubiquitin and heat shock proteins [9,49]. The genesis of CA formation has been correlated to cellular stress, specifically to mitochondrial dysfunction and oxidative stress [50]. The connection with oxidative stress is further supported by data demonstrating the presence of transglutaminase-1 within CA. Transglutaminases are stress-associated enzymes that when activated result in the cross-linking and aggregation of cellular proteins that form the core of the CA [10].

Taken together, the prevailing data suggest that CA serve as protective structures and in this manner share many similar characteristics to Hirano bodies. Hirano bodies were first described in 1965 and are characterized as rod-shaped paracrystalline structures in the neurons of the CNS [51]. Hirano bodies are rich in cytoskelet al. proteins including tau and actin as well as truncated proteins such as TDP-43 [52-54]. Hirano bodies have been found in a number of different neurodegenerative diseases including AD [55], Creutzfeldt-Jacob disease [56], Pick's disease [51] and Parkinson's [57]. However, like for CA, whether or Hirano bodies contribute to the neurodegeneration observed in these disorders is unknown.

Concluding Remarks

The presence of CA within the normal aging brain suggests that these spherical structures are a byproduct of the normal aging process. However, the presence of CA in numerous neurodegenerative diseases and disorders in significant numbers above and beyond what are found in matched controls suggests an alternative role for CA: that they may provide a protective role in these pathological processes by sequestering aggregated protein structures and thus protect cellular structures from further damage. In this manner, CA may play a similar role as to what has been previously described for Hirano bodies and suggest that these structures do not play a passive role but may actually contribute to defense mechanisms that are valiantly attempting to prevent cellular damage in the face of toxic mediators including tau, alpha-synuclein, ubiquitin, and transglutaminases. However, further research is necessary in order to clearly delineate the role of CA in neurodegenerative diseases.


Research reported in this manuscript was supported by National Institutes of Health Grant 1R15AG042781-01A1 and KO Alzheimer's Dementia Foundation (Boise, ID). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

  1. Fleming PD, Cordoza ME, Woods SG, Griesbach EJ, Worcester MA (1987) Corpora amylacea increased in Alzheimer's disease. Neurology 37: 157.

  2. Selmaj K, Pawłowska Z, Walczak A, Koziołkiewicz W, Raine CS, et al. (2008) Corpora amylacea from multiple sclerosis brain tissue consists of aggregated neuronal cells. Acta Biochim Pol 55: 43-49.

  3. Leel-Ossy L (1998) Corpora amylacea in hippocampal sclerosis. J Neurol Neurosurg Psychiatry 65: 614.

  4. Van Paesschen W, Revesz T, Duncan JS (1997) Corpora amylacea in hippocampal sclerosis. J Neurol Neurosurg Psychiatry 63: 513-515.

  5. Chung MH, Horoupian DS (1996) Corpora amylacea: a marker for mesial temporal sclerosis. J Neuropathol Exp Neurol 55: 403-408.

  6. Estupiñán-Díaz BO, Morales-Chacón LM, García-Maeso I, Lorigados-Pedre L, Báez-Martín M, et al. (2015) Corpora amylacea in the neocortex in patients with temporal lobe epilepsy and focal cortical dysplasia. Neurologia 30: 90-96.

  7. Ramsey HJ (1965) Ultrastructure Of Corpora Amylacea. J Neuropathol Exp Neurol 24: 25-39.

  8. Sakai M, Austin J, Witmer F, Trueb L (1969) Corpora amylacea: Isolation, characterization, and significance. Trans Am Neurol Assoc 94: 336-338.

  9. Cissé S, Perry G, Lacoste-Royal G, Cabana T, Gauvreau D (1993) Immunochemical identification of ubiquitin and heat-shock proteins in corpora amylacea from normal aged and Alzheimer's disease brains. Acta Neuropathol 85: 233-240.

  10. Wilhelmus MM, Verhaar R, Bol JG, van Dam AM, Hoozemans JJ, et al. (2011) Novel role of transglutaminase 1 in corpora amylacea formation? Neurobiol Aging 32: 845-856.

  11. Renkawek K, Bosman GJ (1995) Anion exchange proteins are a component of corpora amylacea in Alzheimer disease brain. Neuroreport 6: 929-932.

  12. Singhrao SK, Morgan BP, Neal JW, Newman GR (1995) A functional role for corpora amylacea based on evidence from complement studies. Neurodegeneration 4: 335-345.

  13. Singhrao SK, Neal JW, Piddlesden SJ, Newman GR (1994) New immunocytochemical evidence for a neuronal/oligodendroglial origin for corpora amylacea. Neuropathol Appl Neurobiol 20: 66-73.

  14. Botez G, Rami A (2001) Immunoreactivity for Bcl-2 and C-Jun/AP1 in hippocampal corpora amylacea after ischaemia in humans. Neuropathol Appl Neurobiol 27: 474-480.

  15. KorzhevskiÄ DE, Giliarov AV (2007) [Demonstration of nuclear protein neun in the human brain corpora amylacea]. Morfologiia 131: 75-76.

  16. Hoyaux D, Decaestecker C, Heizmann CW, Vogl T, Schäfer BW, et al. (2000) S100 proteins in Corpora amylacea from normal human brain. Brain Res 867: 280-288.

  17. Meng H, Zhang X, Blaivas M, Wang MM (2009) Localization of blood proteins thrombospondin1 and ADAMTS13 to cerebral corpora amylacea. Neuropathology 29: 664-671.

  18. Notter T, Knuesel I (2013) Reelin immunoreactivity in neuritic varicosities in the human hippocampal formation of non-demented subjects and Alzheimer's disease patients. Acta Neuropathol Commun 1: 27.

  19. Singhrao SK, Neal JW, Newman GR (1993) Corpora amylacea could be an indicator of neurodegeneration. Neuropathol Appl Neurobiol 19: 269-276.

  20. Loeffler KU, Edward DP, Tso MO (1993) Tau-2 immunoreactivity of corpora amylacea in the human retina and optic nerve. Invest Ophthalmol Vis Sci 34: 2600-2603.

  21. Avendano J, Rodrigues MM, Hackett JJ, Gaskins R (1980) Corpora amylacea of the optic nerve and retina: a form of neuronal degeneration. Invest Ophthalmol Vis Sci 19: 550-555.

  22. Yanoff M, Fine B (1979) Ocular Histology. Hagerstown: Harper and Row.

  23. Woodford B, Tso MO (1980) An ultrastructural study of the corpora amylacea of the optic nerve head and retina. Am J Ophthalmol 90: 492-502.

  24. Anzil AP, Herrlinger H, Blinzinger K, Kronski D (1974) Intraneuritic corpora amylacea. Demonstration in orbital cortex of elderly subjects by means of early postmortem brain sampling and electron microscopy. Virchows Arch A Pathol Anat Histol 364: 297-301.

  25. Cramer SF (1981) Benign glandular inclusion in prostatic nerve. Am J Clin Pathol 75: 854-855.

  26. Wolozin BL, Pruchnicki A, Dickson DW, Davies P (1986) A neuronal antigen in the brains of Alzheimer patients. Science 232: 648-650.

  27. Takahashi K, Agari M, Nakamura H (1975) Intra-axonal Corpora amylacea in ventral and lateral horns of the spinal cord. Acta Neuropathol 31: 151-158.

  28. Song W, Zukor H2, Liberman A1, Kaduri S1, Arvanitakis Z3, et al. (2014) Astroglial heme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues. Exp Neurol 254: 78-89.

  29. Leel-Ossy L (2001) New data on the ultrastructure of the corpus amylaceum (polyglucosan body). Pathol Oncol Res 7: 145-150.

  30. Loiseau H, Marchal C, Vital A, Vital C, Rougier A, et al. (1992) Occurrence of polyglucosan bodies in temporal lobe epilepsy. J Neurol Neurosurg Psychiatry 55: 1092-1093.

  31. Nishio S, Morioka T, Kawamura T, Fukui K, Nonaka H, et al. (2001) Corpora amylacea replace the hippocampal pyramidal cell layer in a patient with temporal lobe epilepsy. Epilepsia 42: 960-962.

  32. Radhakrishnan A, Radhakrishnan K, Radhakrishnan VV, Mary PR, Kesavadas C, et al. (2007) Corpora amylacea in mesial temporal lobe epilepsy: clinico-pathological correlations. Epilepsy Res 74: 81-90.

  33. Cherian PJ, Radhakrishnan VV, Radhakrishnan K (2003) The significance of corpora amylacea in mesial temporal lobe epilepsy. Neurol India 51: 277-279.

  34. Kawamura T, Morioka T, Nishio S, Fukui K, Yamasaki R, et al. (2002) Temporal lobe epilepsy associated with hippocampal sclerosis and a contralateral middle fossa arachnoid cyst. Seizure 11: 60-62.

  35. Raine CS (1994) The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 36 Suppl: S61-72.

  36. Mizutani T, Satoh J, Morimatsu Y (1987) Axonal polyglucosan body in the ventral posterolateral nucleus of the human thalamus in relation to ageing. Acta Neuropathol 74: 9-12.

  37. Buervenich S, Olson L, Galter D (2001) Nestin-like immunoreactivity of corpora amylacea in aged human brain. Brain Res Mol Brain Res 94: 204-208.

  38. Averback P (1981) Parasynaptic corpora amylacea in the striatum. Arch Pathol Lab Med 105: 334-335.

  39. Jellinger KA (2007) The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 113: 349-388.

  40. Kalaria RN (2003) Comparison between Alzheimer's disease and vascular dementia: implications for treatment. Neurol Res 25: 661-664.

  41. Kalaria RN, Ballard C (1999) Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13 Suppl 3: S115-123.

  42. Jellinger KA (2013) Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci 5: 17.

  43. Staekenborg SS, van der Flier WM, van Straaten EC, Lane R, Barkhof F, et al. (2008) Neurological signs in relation to type of cerebrovascular disease in vascular dementia. Stroke 39: 317-322.

  44. Kalaria RN (2012) Cerebrovascular disease and mechanisms of cognitive impairment: evidence from clinicopathological studies in humans. Stroke 43: 2526-2534.

  45. Day RJ, Mason MJ, Thomas C, Poon WW, Rohn TT (2015) Caspase-Cleaved Tau Co-Localizes with Early Tangle Markers in the Human Vascular Dementia Brain. PLoS One 10: e0132637.

  46. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, et al. (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100: 10032-10037.

  47. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, et al. (2005) Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging 26: 1015-1022.

  48. Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, et al. (1998) A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 50: 966-971.

  49. Cavanagh JB (1999) Corpora-amylacea and the family of polyglucosan diseases. Brain Res Brain Res Rev 29: 265-295.

  50. Keller JN (2006) Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Res Rev 5: 1-13.

  51. Hirano A (1994) Hirano bodies and related neuronal inclusions. Neuropathol Appl Neurobiol 20: 3-11.

  52. Galloway PG, Perry G, Gambetti P (1987) Hirano body filaments contain actin and actin-associated proteins. J Neuropathol Exp Neurol 46: 185-199.

  53. Galloway PG, Perry G, Kosik KS, Gambetti P (1987) Hirano bodies contain tau protein. Brain Res 403: 337-340.

  54. Rohn TT (2008) Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer's disease. Brain Res 1228: 189-198.

  55. Gibson PH, Tomlinson BE (1977) Numbers of Hirano bodies in the hippocampus of normal and demented people with Alzheimer's disease. J Neurol Sci 33: 199-206.

  56. Cartier L, Gálvez S, Gajdusek DC (1985) Familial clustering of the ataxic form of Creutzfeldt-Jakob disease with Hirano bodies. J Neurol Neurosurg Psychiatry 48: 234-238.

  57. Hirano A, Dembitzer HM, Kurland LT, Zimmerman HM (1968) The fine structure of some intraganglionic alterations. Neurofibrillary tangles, granulovacuolar bodies and "rod-like" structures as seen in Guam amyotrophic lateral sclerosis and parkinsonism-dementia complex. J Neuropathol Exp Neurol 27: 167-182.

International Journal of Anesthetics and Anesthesiology (ISSN: 2377-4630)
International Journal of Blood Research and Disorders   (ISSN: 2469-5696)
International Journal of Brain Disorders and Treatment (ISSN: 2469-5866)
International Journal of Cancer and Clinical Research (ISSN: 2378-3419)
International Journal of Clinical Cardiology (ISSN: 2469-5696)
Journal of Clinical Gastroenterology and Treatment (ISSN: 2469-584X)
Clinical Medical Reviews and Case Reports (ISSN: 2378-3656)
Journal of Dermatology Research and Therapy (ISSN: 2469-5750)
International Journal of Diabetes and Clinical Research (ISSN: 2377-3634)
Journal of Family Medicine and Disease Prevention (ISSN: 2469-5793)
Journal of Genetics and Genome Research (ISSN: 2378-3648)
Journal of Geriatric Medicine and Gerontology (ISSN: 2469-5858)
International Journal of Immunology and Immunotherapy (ISSN: 2378-3672)
International Journal of Medical Nano Research (ISSN: 2378-3664)
International Journal of Neurology and Neurotherapy (ISSN: 2378-3001)
International Archives of Nursing and Health Care (ISSN: 2469-5823)
International Journal of Ophthalmology and Clinical Research (ISSN: 2378-346X)
International Journal of Oral and Dental Health (ISSN: 2469-5734)
International Journal of Pathology and Clinical Research (ISSN: 2469-5807)
International Journal of Pediatric Research (ISSN: 2469-5769)
International Journal of Respiratory and Pulmonary Medicine (ISSN: 2378-3516)
Journal of Rheumatic Diseases and Treatment (ISSN: 2469-5726)
International Journal of Sports and Exercise Medicine (ISSN: 2469-5718)
International Journal of Stem Cell Research & Therapy (ISSN: 2469-570X)
International Journal of Surgery Research and Practice (ISSN: 2378-3397)
Trauma Cases and Reviews (ISSN: 2469-5777)
International Archives of Urology and Complications (ISSN: 2469-5742)
International Journal of Virology and AIDS (ISSN: 2469-567X)
More Journals

Contact Us

ClinMed International Library | Science Resource Online LLC
3511 Silverside Road, Suite 105, Wilmington, DE 19810, USA


Get Email alerts
Creative Commons License
Open Access
by ClinMed International Library is licensed under a Creative Commons Attribution 4.0 International License based on a work at
Copyright © 2017 ClinMed International Library. All Rights Reserved.